These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Alport syndrome. Molecular genetic aspects. Hertz JM Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970 [TBL] [Abstract][Full Text] [Related]
66. Clinical and Functional Consequences of C-Terminal Variants in MCT8: A Case Series. van Geest FS; Meima ME; Stuurman KE; Wolf NI; van der Knaap MS; Lorea CF; Poswar FO; Vairo F; Brunetti-Pierri N; Cappuccio G; Bakhtiani P; de Munnik SA; Peeters RP; Visser WE; Groeneweg S J Clin Endocrinol Metab; 2021 Jan; 106(2):539-553. PubMed ID: 33141165 [TBL] [Abstract][Full Text] [Related]
67. Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. van der Deure WM; Peeters RP; Visser TJ J Mol Endocrinol; 2010 Jan; 44(1):1-11. PubMed ID: 19541799 [TBL] [Abstract][Full Text] [Related]
68. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations. Remerand G; Boespflug-Tanguy O; Tonduti D; Touraine R; Rodriguez D; Curie A; Perreton N; Des Portes V; Sarret C; Dev Med Child Neurol; 2019 Dec; 61(12):1439-1447. PubMed ID: 31410843 [TBL] [Abstract][Full Text] [Related]
69. The Chemical Chaperone Phenylbutyrate Rescues MCT8 Mutations Associated With Milder Phenotypes in Patients With Allan-Herndon-Dudley Syndrome. Braun D; Schweizer U Endocrinology; 2017 Mar; 158(3):678-691. PubMed ID: 27977298 [TBL] [Abstract][Full Text] [Related]
70. Inherited defects in thyroid hormone cell-membrane transport and metabolism. Fu J; Dumitrescu AM Best Pract Res Clin Endocrinol Metab; 2014 Mar; 28(2):189-201. PubMed ID: 24629861 [TBL] [Abstract][Full Text] [Related]
71. Detection of a novel intragenic rearrangement in the creatine transporter gene by next generation sequencing. Yu H; van Karnebeek C; Sinclair G; Hill A; Cui H; Zhang VW; Wong LJ Mol Genet Metab; 2013 Dec; 110(4):465-71. PubMed ID: 24140398 [TBL] [Abstract][Full Text] [Related]
72. Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier. Vatine GD; Al-Ahmad A; Barriga BK; Svendsen S; Salim A; Garcia L; Garcia VJ; Ho R; Yucer N; Qian T; Lim RG; Wu J; Thompson LM; Spivia WR; Chen Z; Van Eyk J; Palecek SP; Refetoff S; Shusta EV; Svendsen CN Cell Stem Cell; 2017 Jun; 20(6):831-843.e5. PubMed ID: 28526555 [TBL] [Abstract][Full Text] [Related]
73. Tissue-specific effects of mutations in the thyroid hormone transporter MCT8. Kersseboom S; Visser TJ Arq Bras Endocrinol Metabol; 2011 Feb; 55(1):1-5. PubMed ID: 21468514 [No Abstract] [Full Text] [Related]
74. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Dumitrescu AM; Liao XH; Best TB; Brockmann K; Refetoff S Am J Hum Genet; 2004 Jan; 74(1):168-75. PubMed ID: 14661163 [TBL] [Abstract][Full Text] [Related]
75. Deletion of exon 1 of the SLC16A2 gene: a common occurrence in patients with Allan-Herndon-Dudley syndrome. García-de Teresa B; González-Del Angel A; Reyna-Fabián ME; Ruiz-Reyes Mde L; Calzada-León R; Pérez-Enríquez B; Alcántara-Ortigoza MA Thyroid; 2015 Mar; 25(3):361-7. PubMed ID: 25517855 [TBL] [Abstract][Full Text] [Related]
76. Pregnancy in women heterozygous for MCT8 mutations: risk of maternal hypothyroxinemia and fetal care. Ramos HE; Morandini M; Carré A; Tron E; Floch C; Mandelbrot L; Neri N; De Sarcus B; Simon A; Bonnefont JP; Amiel J; Desguerre I; Valayannopoulos V; Castanet M; Polak M Eur J Endocrinol; 2011 Feb; 164(2):309-14. PubMed ID: 21098685 [TBL] [Abstract][Full Text] [Related]
77. Novel mutations in SLC16A2 associated with a less severe phenotype of MCT8 deficiency. Masnada S; Groenweg S; Saletti V; Chiapparini L; Castellotti B; Salsano E; Visser WE; Tonduti D Metab Brain Dis; 2019 Dec; 34(6):1565-1575. PubMed ID: 31332729 [TBL] [Abstract][Full Text] [Related]
78. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Schwartz CE; May MM; Carpenter NJ; Rogers RC; Martin J; Bialer MG; Ward J; Sanabria J; Marsa S; Lewis JA; Echeverri R; Lubs HA; Voeller K; Simensen RJ; Stevenson RE Am J Hum Genet; 2005 Jul; 77(1):41-53. PubMed ID: 15889350 [TBL] [Abstract][Full Text] [Related]
79. Minireview: thyroid hormone transporters: the knowns and the unknowns. Visser WE; Friesema EC; Visser TJ Mol Endocrinol; 2011 Jan; 25(1):1-14. PubMed ID: 20660303 [TBL] [Abstract][Full Text] [Related]
80. Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan-Herndon-Dudley Syndrome. Novara F; Groeneweg S; Freri E; Estienne M; Reho P; Matricardi S; Castellotti B; Visser WE; Zuffardi O; Visser TJ Hum Mutat; 2017 Mar; 38(3):260-264. PubMed ID: 27805744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]